Arecor Therapeutics PLC Posting of 2023 Annual Report and Notice of AGM
31 Maggio 2024 - 5:05PM
RNS Regulatory News
RNS Number : 6699Q
Arecor Therapeutics PLC
31 May 2024
POSTING OF ARECOR 2023 ANNUAL
REPORT AND NOTICE OF AGM
Cambridge, UK, 31 May 2024. Arecor
Therapeutics plc (AIM: AREC), the biopharmaceutical company
advancing today's therapies to enable healthier lives, announces that it has today
published and posted to shareholders the Annual Report and Accounts
for the year ended 31 December 2023 and Notice of the Annual
General Meeting ("AGM") which will be held at the offices of Covington & Burling LLP, 22 Bishopsgate,
London EC2N 4BQ, on 28 June 2024 at 12.00
p.m. (BST).
The Annual Report and Accounts and
notice of AGM are also available to view on, and download from, the
Company's website at https://arecor.com/investor-centre/shareholder-information/
-ENDS-
For more
information, please contact:
|
Arecor
Therapeutics plc
|
www.arecor.com
|
|
Dr Sarah Howell, Chief Executive
Officer
|
Tel: +44 (0) 1223 426060
Email: info@arecor.com
|
|
|
|
|
Susan Lowther, Chief Financial
Officer
|
Tel: +44 (0) 1223 426060
Email: info@arecor.com
|
|
|
|
|
|
|
|
Panmure Gordon
(UK) Limited (NOMAD and Broker)
Freddy Crossley, Emma Earl (Corporate
Finance)
Rupert Dearden (Corporate Broking)
|
Tel: +44 (0) 20 7886 2500
|
|
|
|
|
WG Partners
LLP (Financial
Advisor)
Nigel Barnes, Satheesh Nadarajah
David Wilson, Claes
Spang
|
Tel: +44
(0)203 705 9321
|
|
|
|
|
ICR
Consilium
|
|
|
Chris Gardner, David Daley, Lindsey
Neville
|
Tel: +44 (0) 20 3709 5700
Email:
arecor@consilium-comms.com
|
Notes to
Editors
About
Arecor
Arecor Therapeutics plc is a globally focused
biopharmaceutical company transforming patient care by bringing
innovative medicines to market through the enhancement of
existing therapeutic products. By applying our innovative
proprietary technology platform, Arestat™, we are developing
an internal portfolio of proprietary products in diabetes and other
indications, as well as working with leading pharmaceutical and
biotechnology companies to deliver therapeutic products. The
Arestat™ platform is supported by an extensive patent
portfolio.
For further details please see our
website, www.arecor.com
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact
rns@lseg.com or visit
www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our
Privacy
Policy.
END
NOABGGDUBGXDGSB
Grafico Azioni Arecor Therapeutics (LSE:AREC)
Storico
Da Feb 2025 a Mar 2025
Grafico Azioni Arecor Therapeutics (LSE:AREC)
Storico
Da Mar 2024 a Mar 2025
